


Supplementary Figure 4



Supplementary Figure 4. HPT axis, hypothalamic neuropeptides, and blood glucose following acute i3vt GW9662.

a) Plasma TSH from HFD-fed rats 5 h after receiving 1 μ g GW9662 or its vehicle i3vt (T-test) **b**) Plasma T3 from HFD-fed rats 5 h after receiving 1 μ g GW9662 or its vehicle i3vt (T-test) **c,d**) Relative mRNA expression of hypothalamic pro-opiomelanocortin (POMC), Agouti-related peptide (AgRP), Neuropeptide-Y (NPY), Cocaine and amphetamine-related transcript (CART), Thyrotropin-releasing hormone (TRH), or Corticotropin-releasing hormone (CRH) at 3.5 h (**c**) or 5 h (**d**) following i3vt administration of 1 μ g GW9662 or its vehicle (T-tests). **e**) Blood glucose at 5 h following 1 μ g i3vt GW9662 or its vehicle (T-test). * = $p < 0.05$, ** = $p < 0.01$. The mean for each group is depicted \pm S.E., $n = 5-10$ rats per group.